List view / Grid view
Alzheimer’s disease remains one of the largest challenges for the global ageing population. In this article, Victoria Rees, Editor of Drug Target Review, reviews some of the latest research, highlighting how progress has been made in understanding tau as well as how to potentially target this protein as a therapeutic strategy against…
Learn how R&D Systems™ Avi-tag biotinylated proteins can be used as an alternative to amine biotin coupling in surface plasmon resonance experiments.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).
Scientists at UTHealth Houston have developed an agonistic antibody that reduced the amyloid pathology in mice with Alzheimer’s disease.
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
The new labelling system includes a variant of ascorbate peroxidase which is fused to another protein that is known to seek out exosomes.
Trust in your results — Experience the benefits of iQue® advanced flow cytometry.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The approach mimics the physical forces exerted by T cells as they crawl over host cells, could help scientists develop more effective cancer immunotherapies.
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
This article outlines the advantages of using R&D Systems™ fluorescent-labeled proteins to directly stain and detect CAR+ cells by flow cytometry.
